

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30

## Cytosolic PCNA interacts with S100A8 and controls an inflammatory subset of neutrophils in COVID-19

Rodrigo de Oliveira Formiga<sup>1,2</sup>, Lucie Pesenti<sup>1</sup>, Maha Zohra Ladjemi<sup>1</sup>, Philippe Frachet<sup>3</sup>, Muriel Andrieu<sup>1</sup>, Souganya Many<sup>1</sup>, Vaarany Karunanithy<sup>1</sup>, Karine Bailly<sup>1</sup>, Théo Dhôte<sup>1</sup>, Manon Castel<sup>1</sup>, Christophe Rousseau<sup>1</sup>, Marick Starick<sup>2</sup>, Edroaldo Lummertz da Rocha<sup>2</sup>, Emilia Puig Lombardi<sup>4</sup>, Vanessa Granger<sup>5,6</sup>, Sylvie Chollet-Martin<sup>5,6</sup>, Luc De Chaisemartin<sup>5,6</sup>, Luc Mouthon<sup>1,7</sup>, Fernando Spiller<sup>2</sup>, Anne Hosmalin<sup>1</sup>, Margarita Hurtado-Nedelec<sup>8</sup>, Clémence Martin<sup>1,9</sup>, Frédéric Pène<sup>1,10</sup>, Pierre-Regis Burgel<sup>1,9</sup>, Léa Tourneur<sup>1</sup>, Véronique Witko-Sarsat<sup>1,\*</sup>

<sup>1</sup>Université Paris Cité, INSERM U1016, CNRS 8104, Institut Cochin, Paris, France; <sup>2</sup>Laboratory of Immunobiology, Department of Pharmacology, Federal University of Santa Catarina (UFSC), Florianopolis, Santa Catarina, Brazil; <sup>3</sup>Université Grenoble Alpes, CEA, CNRS, IBS, Grenoble, France; <sup>4</sup>Bioinformatics Core Platform, INSERM UMR1163, Imagine Institute, Université Paris Cité, Paris, France; <sup>5</sup>APHP, Immunology department, Auto-immunity, hypersensitivities and biologicals, Bichat Hospital, Paris, France; <sup>6</sup>Paris-Saclay University, INSERM, Inflammation, microbiome and immunosurveillance, Châtenay-Malabry, France; <sup>7</sup> Department of Internal Medicine, AP-HP, Cochin Hospital, Paris, France; <sup>8</sup>Department of Immunology and Hematology, UF Immune Dysfunctions, HUPNVS, Bichat Hospital, Paris, France; <sup>9</sup>Department of Pneumology, AP-HP, Cochin Hospital, Paris, France; <sup>10</sup>Department of Intensive Medicine and Reanimation, AP-HP, Cochin Hospital, Paris, France.

Correspondence: Véronique Witko-Sarsat, Institut Cochin - Bâtiment Roussy, 27 Rue du Faubourg Saint-Jacques - 75014 PARIS ; e-mail: [veronique.witko@inserm.fr](mailto:veronique.witko@inserm.fr)

**Running title:** PCNA-S100A8 interaction in neutrophils in COVID-19

**Key words:** Neutrophils; PCNA; S100A8, COVID-19

31 **Abstract**

32

33 Neutrophils are key players in the hyperinflammatory response upon SARS-CoV-2 infection. We have  
34 previously described that cytosolic proliferating cell nuclear antigen (PCNA) controls neutrophil survival  
35 and NADPH oxidase-dependent ROS production. We here show that both PCNA and S100A8 expression  
36 and interaction were elevated in neutrophils from patients with COVID-19 compared to healthy donors  
37 and this was correlated with disease severity. Increased PCNA expression was accompanied by a  
38 decreased apoptosis and increased NADPH-oxidase activity in neutrophils from COVID-19 patients  
39 compared to healthy donors. These effects, as well as the interaction between PCNA and S100A8, were  
40 potently counteracted by T2 amino alcohol (T2AA), a PCNA inhibitor, demonstrating that the PCNA  
41 scaffold orchestrated neutrophil activation. Notably, the interaction between PCNA-S100A8 was more  
42 intense in the CD16<sup>high</sup>-CD62L<sup>low</sup> activated neutrophil subset. We propose that PCNA-S100A8 complex acts  
43 as potential driver for neutrophil dysregulation in COVID-19 and show for the first time that the PCNA  
44 scaffold is a decisive component of both neutrophil activation and heterogeneity.

45

## 46 Introduction

47 Neutrophils are key players in the innate immune response and form the first line of defense against  
48 infectious agents, as they employ well-characterized anti-microbial strategies, such as phagocytosis or  
49 release of reactive oxygen species (ROS)<sup>1</sup>, neutrophil extracellular traps (NETs)<sup>2</sup> and other pro-  
50 inflammatory mediators.<sup>3,4</sup> Recent unexpected biological features, such as their phenotypic and functional  
51 heterogeneity,<sup>5</sup> their extended lifespan under certain pathological conditions have highlighted their  
52 crucial role in controlling adaptive immune responses.<sup>6-8</sup> Increased neutrophil counts and newly  
53 identified subsets with characteristics of immaturity, immunosuppression, activation, and metabolic  
54 rewiring in both circulation and infiltrated into the respiratory tract may be pivotal clinical aspects of  
55 severe Coronavirus Disease (COVID)-19 caused by severe acute respiratory syndrome coronavirus 2 (SARS-  
56 CoV-2).<sup>8</sup> Upon SARS-CoV-2 infection, a wide spectrum of clinical outcomes may appear, ranging from self-  
57 limited asymptomatic<sup>9</sup> or mild disease to severe cases, the last marked by thromboembolic events,<sup>10</sup>  
58 dysregulated immune response,<sup>11</sup> and respiratory distress and multiorgan failure.<sup>8,12-15</sup>  
59 In COVID-19 the circulating levels of calprotectin, also known as S100A8/A9, are highly abundant and are  
60 associated with immune imbalance and expansion of aberrant neutrophil subpopulations that correlated  
61 with disease severity.<sup>16-17</sup> Indeed, calprotectin is a potential biomarker in a wide number of inflammatory  
62 conditions in which neutrophils are involved, such as autoimmune vasculitis,<sup>18</sup> arthritis,<sup>19</sup> cardiovascular,  
63 and metabolic disorders. The S100A8/A9 is constitutively expressed in neutrophils and monocytes, a Ca<sup>2+</sup>  
64 sensor, participates in cytoskeleton rearrangement and arachidonic acid metabolism.<sup>20</sup> Neutrophil  
65 secretion of S100A8/A9 might act as an extracellular signaling mediator.<sup>21</sup>  
66 To gain insights into the molecular mechanisms involved in neutrophil dysregulation and reprogramming  
67 observed in COVID-19 patients, we examined the expression and function of the proliferating cell nuclear  
68 antigen (PCNA), which we previously described as a key regulator of neutrophil fate.<sup>22,23</sup> PCNA is a  
69 scaffolding protein expressed in the nucleus of proliferating cells where it controls DNA replication and  
70 repair.<sup>24,25</sup> By contrast, in neutrophils, which are non-proliferative cells, PCNA is exclusively cytoplasmic<sup>26</sup>  
71 and interacts with procaspases to promote neutrophil survival.<sup>22,27</sup> Notably, T2 amino alcohol (T2AA)<sup>28,29</sup>,  
72 a small molecule inhibitor that specifically binds to PCNA promotes the resolution of inflammation in a  
73 model of murine colitis. Proteomic analysis of neutrophil PCNA interactome identified a diversity of  
74 proteins involved in different functions, including cytoskeletal regulation, metabolism,<sup>30</sup> and NADPH  
75 oxidase. Indeed, PCNA interacts directly with p47<sup>phox</sup>, a NADPH oxidase subunit, to control the oxidative  
76 burst.<sup>31</sup> Likewise, calprotectin promotes NADPH oxidase complex assembly and ROS generation through

77 direct interactions between S100A8 and the cytosolic subunit p67<sup>phox32</sup> and between S100A9 and the  
78 cytochrome b558 protein, gp91<sup>phox</sup>.<sup>33</sup>

79 The aim of this study is to examine whether and how the cytosolic proteins PCNA and S100A8/A9 may be  
80 involved in the dysregulated function of neutrophils in COVID-19 patients of various severity. We herein  
81 identify a pivotal role of cytosolic PCNA in promoting survival and NADPH oxidase-dependent ROS  
82 production in neutrophils, notably through its enhanced interaction with the S100A8 protein. Most  
83 strikingly, this PCNA-S100A8 interaction in neutrophil cytosol was found in a particular neutrophil subset  
84 and was related to COVID-19 severity.

85

## 86 **Results**

### 87 **Increased PCNA expression is associated with increased survival in neutrophils from COVID-19 patients**

88 Western blot analysis of PCNA in neutrophils from HD and COVID-19 patients showed an increase in PCNA  
89 cytosolic expression correlating with disease severity with significant differences between critical patients  
90 and HD, as well as severe patients and HD. However, no significant changes were found between  
91 HD/moderate or severe/critical patients (Figures 1A-B). Increased PCNA expression in neutrophils from  
92 both severe and critical COVID-19 patients was confirmed by immunofluorescence labelling of PCNA that  
93 displayed a cytoplasmic pattern (Figures 1C-D). Re-analysis of publicly available scRNA-seq data<sup>16,41</sup>  
94 pointed to no changes in PCNA mRNA in circulating or respiratory tract infiltrating neutrophils in severe  
95 COVID-19 patients (Supplemental Figure 2). Notably, the PCNA cytosolic expression was correlated with  
96 circulating NETs (Figures 1E-F), neutrophil elastase (Figures 1G-H) and calprotectin levels (Figures 1I-J)  
97 strongly suggesting that cytosolic PCNA was pivotal in neutrophil activation state and was reminiscent of  
98 systemic inflammation.

99 We next evaluated the ability of neutrophils from COVID-19 patients to undergo spontaneous apoptosis  
100 after a 16h *in vitro* incubation by measuring annexin-V binding on externalized phosphatidylserine. As  
101 expected, neutrophils from severe and critical COVID-19 patients were significantly more viable, less  
102 apoptotic, and less necrotic (evaluated by 7AAD labelling) than HD neutrophils (Figure 2A-C). Notably,  
103 T2AA, a PCNA inhibitor,<sup>28,29</sup> significantly decreased the survival of COVID-19 neutrophils by increasing  
104 apoptosis (Figure 2A-C). This increased survival was confirmed by a significantly stronger DiOC6 labelling  
105 thereby indicating a preserved mitochondrial membrane potential ( $\Delta\psi_m$ ) during overnight incubation as  
106 compared to HD. This sustained  $\Delta\psi_m$  was reversed by disrupting the PCNA scaffold by T2AA (Figure 2D),  
107 again highlighting the key role of PCNA in survival of COVID-19 neutrophils.

108 In accordance with the notion that cytosolic PCNA inhibits apoptosis,<sup>22</sup> Western blot analysis confirmed  
109 that PCNA expression was significantly decreased after apoptosis in HD neutrophils. By contrast, COVID-  
110 19 neutrophils maintained high amounts of PCNA even after spontaneous apoptosis and this was  
111 particularly pronounced in critically ill patients who display the highest level of PCNA (Figure 2E).

112

### 113 **Cytosolic PCNA controls sustained NADPH oxidase-dependent ROS production in neutrophils from** 114 **COVID-19 patients**

115 We next examined NADPH oxidase-dependent ROS production to evaluate the activation state of COVID-  
116 19 neutrophils. No significant difference in ROS production was found between neutrophils from COVID-  
117 19 patients with a moderate severity compared to HD at basal state or after *in vitro* activation by PMA,

118 opsonized zymosan or f-MLF. By contrast, neutrophils from severe and critical COVID-19 patients had a  
119 significant increase in basal ROS production compared to HD showing that they were activated in the  
120 absence of *in vitro* stimulus (Figure 3A). ROS production was significantly increased after PMA, opsonized  
121 zymosan, or f-MLF stimulation in severe COVID-19 patients as compared with HD, suggesting that this  
122 increased ROS production was associated with the severity of the disease to some extent. Notably,  
123 inhibition of the PCNA scaffold by T2AA resulted in a significant decrease in either basal (Figure 3A) or  
124 stimulated ROS production (Figure 3B-D) in COVID-19 neutrophils whatever the severity of the disease.  
125 Accordingly, T2AA decreased NADPH-oxidase dependent ROS production at higher concentrations in  
126 COVID-19 compared to HD neutrophils (Supplemental Figure 3). Taken together, our data suggest that  
127 PCNA sustains NADPH oxidase-dependent ROS production in COVID-19 neutrophils.

128 We previously showed that PCNA can directly bind to the cytosolic p47<sup>phox</sup> protein, acting as a chaperone  
129 to promote NADPH oxidase activation.<sup>31</sup> We here confirmed that the PCNA-p47<sup>phox</sup> association evaluated  
130 by a proximity ligation assay was detected in HD neutrophils at basal state but was absent after PMA  
131 activation as previously reported.<sup>37</sup> By contrast, the PCNA-p47<sup>phox</sup> association was undetectable in  
132 neutrophils from severe COVID-19 patients (Figure 2E-F) strongly supporting the notion that they were  
133 activated at the basal state.

134

135

### 136 **S100A8 is a new partner of PCNA which is overexpressed in neutrophils cytosols from COVID-19 patients**

137 S100A8 or S100A9 have been described to promote NADPH oxidase activity through their association with  
138 cytosolic NADPH oxidase components.<sup>32,33</sup> Since calprotectin serum levels are positively correlated with  
139 neutrophil activation and COVID-19 severity,<sup>16,42</sup> we next tested whether S100A8 or S100A9 could be part  
140 of the PCNA scaffold thereby supporting neutrophil dysregulation in COVID-19. Surface plasmon  
141 resonance (SPR) was carried out to examine whether PCNA could directly interact with either S100A8 or  
142 S100A9 or with the dimeric S100A8/A9 calprotectin. Our data unambiguously showed that there was a  
143 direct S100A8 association with immobilized PCNA in a concentration-dependent manner (0.1-2 $\mu$ M) with  
144 an equilibrium dissociation constant ( $K_D$ ) value within the micromolar range (Figure 4A; Table 2). By  
145 contrast, S100A9 and the S100A8/A9 heterodimer failed to associate with PCNA when assayed under the  
146 same experimental settings (Figure 4B; Table 2). We confirmed, using a proximity ligation assay, that PCNA  
147 and S100A8 were associated within the cytoplasm under basal conditions in neutrophils from both HD  
148 and COVID-19 patients but the PCNA-S100A8 proximity-induced fluorescence intensity was significantly  
149 increased in the latter. Notably, T2AA treatment, by interfering with the PCNA scaffold, significantly

150 blunted the PCNA-S100A8 interaction (Figure 4C-D). Pertinently, using Western blot analysis, we observed  
151 an increased S100A8 cytosolic levels in COVID-19 neutrophils according to disease severity (Figure 4 E-F),  
152 showing positive correlation with PCNA expression (Figure 4G). S100A8 immunofluorescence in  
153 neutrophils from HD and severe COVID patients confirmed its cytoplasmic localization (Figure 4H).  
154 Increased fluorescence intensity consistent with increased S100A8 expression was observed in COVID-19  
155 neutrophils compared to those of HD (Figure 4I). Notably, analysis of publicly available scRNA-seq data<sup>16,41</sup>  
156 showed that S100A8 and S100A9 mRNA percentage and average of expression were altered in COVID-19  
157 peripheral neutrophils, and high S100A8 mRNA levels were detected in respiratory tract infiltrating  
158 neutrophils, showing higher expression levels in critical over moderate patients (Supplemental Figures 2).  
159

#### 160 **Neutrophils from COVID-19 patients present altered phenotype related with activation and immaturity**

161 Neutrophils from both severe and critical COVID-19 patients showed increased levels of adhesion  
162 molecules such as integrin CD11b, CD66b (CEACAM8), the receptor-linked protein tyrosine phosphatase  
163 CD45, the metabolic marker lectin-like oxidized low-density lipoprotein receptor-1 (LOX-1) and  
164 programmed cell death protein ligand 1 (PDL-1), as well as decreased levels of CD62L (L-selectin) strongly  
165 suggesting that neutrophil from severe and critical COVID-19 patients were activated (Figure 5A).  
166 Moreover, a decreased expression of neutral endopeptidase CD10 was observed in COVID-19 patients  
167 compared to HD. Frequency of neutrophils expressing CD10 was decreased while frequency of those  
168 expressing LOX-1, PDL-1, Siglec-3 CD33 and CD114 was increased compared to HD (Supplemental Figure  
169 4). Non-supervised analysis of neutrophils from HD, severe and critical COVID-19 patients showed an  
170 overall decrease in CD62L and increase in CD11b expression in the critical COVID-19 group (Figure 5B). We  
171 identified an enrichment of a neutrophil subset in critical COVID-19 patients, composed of very mature  
172 neutrophils (CD10<sup>high</sup>), with a particularly high activation state (CD11b<sup>high</sup>, CD66b<sup>high</sup> and a LOX-1<sup>high</sup> and  
173 CD114<sup>high</sup> expression. The expansion of this hyperactivated subset of neutrophils is consistent with the  
174 overwhelming inflammatory state of critical COVID-19 patients.

175

#### 176 **PCNA-S100A8 cytosolic interaction is increased in an hyperactivated subset of CD16<sup>high</sup>/CD62L<sup>low</sup>** 177 **neutrophils in COVID-19**

178 Owing to this neutrophil heterogeneity in COVID-19 patients, we next reasoned that the PCNA-S100A8  
179 interaction may be associated with a particular subset of neutrophils endowed with specific functions. To  
180 address this issue, we evaluated the phenotype of neutrophils using a previously described gate strategy<sup>43</sup>

181 according to the CD16/CD62L staining pattern. In HD, most neutrophils presented high levels of CD16 and  
182 CD62L (CD16<sup>high</sup>/CD62L<sup>high</sup>), representing the conventional phenotype while the other subsets  
183 (CD16<sup>high</sup>/CD62L<sup>low</sup>, CD16<sup>low</sup>/CD62L<sup>low</sup> and CD16<sup>low</sup>/CD62L<sup>high</sup>) were approximately 1%. In severe and critical  
184 COVID-19, we observed an expansion of neutrophil subsets presenting CD16<sup>high</sup>/CD62L<sup>low</sup> (2),  
185 CD16<sup>low</sup>/CD62L<sup>low</sup> (3) and CD16<sup>low</sup>/CD62L<sup>high</sup> (4) characteristics and a decrease in the conventional  
186 CD16<sup>high</sup>/CD62L<sup>high</sup> neutrophils was found (Figure 6A-B).

187 Next, a Duolink proximity ligation assay was performed in combination with CD16/CD62L surface marker  
188 immunolabelling and was analyzed by flow cytometry. In HD, we noticed that the PCNA-S100A8  
189 interaction was more intense in the conventional CD16<sup>high</sup>/CD62L<sup>high</sup> subset (1) compared to the other  
190 subsets. By contrast, in severe and critical COVID-19, the PCNA-S100A8 interaction was more intense in  
191 the highly activated cells (CD16<sup>high</sup>/CD62L<sup>low</sup>) (2) than in the conventional CD16<sup>high</sup>/CD62L<sup>high</sup> subset,  
192 strongly suggesting that the mechanisms leading to PCNA-S100A8 interaction could be different between  
193 HD and COVID-19 patients (Figure 6C). This was further corroborated by the measurement of ROS  
194 production after DCFCH staining combined with surface marker labelling analyzed by flow cytometry.  
195 Remarkably, at the basal state, every neutrophil subset from COVID-19 patients produced more ROS than  
196 their counterparts in HD (Figure 6D). This was also observed after PMA or opsonized zymosan stimulation  
197 (Supplemental Figure 5) thereby confirming the sustained NADPH-oxidase-dependent ROS production.  
198 Nonetheless, the ability of each subset to produce ROS in relation with the PCNA-S100A8 interaction  
199 seems to be different between HD and COVID-19 patients. In HD neutrophils, despite a lower level of  
200 PCNA-S100A8 interaction the CD16<sup>high</sup>/CD62L<sup>low</sup> (2) subset (which represents less than 2% of the  
201 neutrophils) ROS production is higher in this subset compared to the conventional CD16<sup>high</sup>/CD62L<sup>high</sup> (1)  
202 subset. In contrast, in COVID-19 neutrophils, the highest ROS production is observed in the  
203 CD16<sup>high</sup>/CD62L<sup>low</sup> (2) subset which also has the highest level of PCNA-S100A8 interaction strongly  
204 suggesting that the PCNA-S100A8 interaction differentially affects ROS production in HD versus COVID-19  
205 neutrophils. Furthermore, in COVID-19, the CD16<sup>high</sup>/CD62L<sup>low</sup> subset (2) had the largest expression of  
206 CD11b (Figure 6E) and LOX-1 (Figure 6F), while showing decreased levels of CD10 when compared to  
207 CD16<sup>high</sup>/CD62L<sup>high</sup> neutrophils (Figure 6G). In conclusion, the PCNA-S100A8 interaction is related to the  
208 production of large amounts of ROS and took place in a specific subset of mature and hyperactivated  
209 neutrophils from patients with severe COVID-19.

210

211



## 212 Discussion

213 An excessive inflammatory response and dysregulated neutrophil phenotype are hallmarks of COVID-19  
214 infection<sup>15,21,44–51</sup> but the molecular defects in the control of neutrophil functions are still unknown. PCNA  
215 is a highly conserved scaffolding protein originally described in the nuclei of proliferating cells as a maestro  
216 of the replication.<sup>24,25</sup> Indeed, the latter process requires a myriad of proteins that should interact together  
217 in a tightly regulated manner to maintain genome integrity.<sup>52,53</sup> Likewise, neutrophil cytosolic PCNA  
218 orchestrates a protein scaffold that controls neutrophil functions including apoptosis, NADPH oxidase  
219 activity, and metabolism.<sup>30,31</sup> In addition, PCNA is a key regulator of neutrophil survival through  
220 sequestration of procaspases to prevent their activation. During apoptosis, PCNA is degraded by the  
221 proteasome, thereby allowing the release of active caspases.<sup>22</sup> In addition, the PCNA scaffold is extremely  
222 versatile in response to neutrophil activation but until now all the functions of cytosolic PCNA are poorly  
223 understood.

224 We first demonstrated that PCNA protein levels were increased in the cytosol of neutrophils according to  
225 COVID-19 severity. Of note, publicly available databases<sup>16,41</sup> have not reported any increased PCNA mRNA  
226 in neutrophils from COVID-19 patients, whereas a proteomic analysis performed on neutrophil lysates has  
227 reported that PCNA was significantly upregulated in severe COVID-19 patients.<sup>15</sup> This lack of  
228 transcriptional regulation of PCNA in neutrophils is in keeping with our previous finding showing that  
229 PCNA expression is significantly increased in neutrophils from donors treated with G-CSF or from patients  
230 with chronic inflammatory disease without any mRNA modulation.<sup>22</sup> Notably, in COVID-19 patients,  
231 cytosolic PCNA levels were correlated with circulating markers of neutrophil-derived mediators such as  
232 MPO-associated DNA (NETs), neutrophil elastase, or more importantly, with seric calprotectin  
233 (S100A8/A9) concentration, this latter being a prognostic marker of the severity of the COVID-19.<sup>16</sup> Indeed,  
234 previous studies report its altered mRNA transcription in both circulating and respiratory tract infiltrated  
235 neutrophils.<sup>16,41</sup> We show for the first time that cytosolic S100A8 levels were significantly increased in  
236 cytosols from COVID-19 neutrophils and that they correlated with those of PCNA. Moreover, PCNA  
237 cytosolic levels were highly sustained even under physiological apoptosis conditions in neutrophils from  
238 severe/critical COVID-19 patients, thus maintaining their survival. S100A8, mainly localized in neutrophil  
239 cytosols and released in culture supernatants in association with NETs<sup>54</sup>, acts as a pro-survival factor  
240 suppressing neutrophil apoptosis via a TLR4 and NF- $\kappa$ B dependent mechanism.<sup>55,56</sup> Hence, we concluded  
241 that both PCNA and S100A8 act together, favoring neutrophil survival and promoting their persistence in  
242 inflammation sites during serious cases of COVID-19 thereby contributing to the worsening of critical  
243 COVID-19 patients.

244 We previously demonstrated that PCNA is directly associated with the phox homology domain of the  
245 p47<sup>phox</sup>, a key subunit of NADPH-oxidase to regulate ROS production in human neutrophils.<sup>31</sup> At basal  
246 state, this association prevents NADPH oxidase activation, whereas upon activation, PCNA acts as a  
247 chaperone by favoring its assembly and then dissociates from the p47<sup>phox</sup> protein. Here, we showed that  
248 the association between PCNA and p47<sup>phox</sup> was disrupted in neutrophils from COVID-19 patients  
249 suggesting a defect in this gate keeper function of PCNA on NADPH oxidase and presumably, a modified  
250 PCNA scaffold. S100A8/S100A9 is also implicated in the positive modulation of the NADPH oxidase via  
251 molecular interactions with p67<sup>phox</sup>, Rac-2,<sup>32</sup> and cytochrome b<sub>558</sub>,<sup>33</sup> respectively the cytosolic and  
252 membrane associated components of the enzyme. We provide evidence that during COVID-19 PCNA was  
253 preferentially associated with S100A8, a process dramatically inhibited by the PCNA scaffold inhibitor  
254 T2AA, thereby suggesting that the PCNA-S100A8 cytosolic partnership may potentiate NADPH-oxidase  
255 activity, reinforcing the concept of PCNA as a key oxidative burst modulator in COVID-19. Unraveling the  
256 molecular details of this PCNA-S100A8 interaction will require further structural biology experiments to  
257 determine the precise PCNA interacting domain in S100A8.<sup>57,58</sup> Nonetheless, our findings may provide the  
258 basis of a PCNA targeted therapy to specifically dampen this overactivation of NADPH oxidase. Using  
259 phenotyping analysis combined with single cell analysis a robust enrichment of CD16<sup>low</sup> neutrophil subsets  
260 characterized by immaturity<sup>59</sup> and activation (CD62L<sup>low</sup>) has been observed in severe COVID-19 patients.<sup>60–</sup>  
261 <sup>62</sup> Those cells are also characterized by higher levels of CD66b, LOX-1, and CD24, which are associated with  
262 early stages of neutrophil development in COVID-19.<sup>61,63</sup> In another study, LOX-1-expressing immature  
263 neutrophils are suggested to identify critically ill COVID-19 patients at risk of thrombotic complications.<sup>64</sup>  
264 Regarding neutrophil phenotyping, we obtained similar results indicating that COVID-19 neutrophils are  
265 basally activated with altered levels of CD11b, CD45, CD114 and CD62L, and characteristics of immaturity  
266 and immunosuppression indicated by LOX-1, CD10 and CD16 assessment. Additionally, we found  
267 neutrophils from COVID-19 express higher surface levels of PDL-1 and CD33 (Siglec-3), markers associated  
268 with immunosuppression.<sup>21,61,65–67</sup> Determination of the CD16/CD62L subsets in various conditions has  
269 proven to be a reliable method to approach the phenotypic and functional analysis of neutrophil  
270 diversity<sup>43,59</sup>. Neutrophils at homeostasis present very uniform expression of CD16 and CD62L  
271 (CD16<sup>high</sup>/CD62L<sup>high</sup>) that progressively changes by the appearance of two other subpopulations after  
272 intravenous LPS challenge, CD16<sup>low</sup>/CD62L<sup>high</sup> and CD16<sup>high</sup>/CD62L<sup>low</sup>.<sup>43</sup> According to a morphological and  
273 functional analysis of those two subsets, CD16<sup>low</sup>/CD62L<sup>high</sup> have banded nuclei indicating immaturity and  
274 show increased resistance to physiological apoptosis.<sup>43</sup> This subset is characteristic of acute inflammation  
275 observed in LPS exposure, bacterial sepsis, acute trauma<sup>68</sup>. In contrast, CD16<sup>high</sup>/CD62L<sup>low</sup> neutrophils

276 present hyper segmented nuclei, high expression of activation markers, such as CD11b, CD11c and CD54  
277 (ICAM), increased NADPH-oxidase activity, and T cell suppression effects.<sup>43</sup> Although this CD16<sup>high</sup>/  
278 CD62L<sup>low</sup> subset can be detected in some acute condition such as LPS injection, it seems to be a hallmark  
279 of a chronic inflammatory challenge such as trauma or COVID-19. Notably, in the COVID-19 patients  
280 returning from ICU patients, the sorted CD16<sup>high</sup>/ CD62L<sup>low</sup> subset had a hypersegmented nuclear  
281 morphology and show an increased CD11b expression suggesting an activated state. Accordingly, we also  
282 observed that in severe and critical COVID-19 neutrophils were CD16<sup>high</sup>/CD62L<sup>high</sup>, CD16<sup>high</sup>/CD62L<sup>low</sup> and  
283 CD16<sup>low</sup>/CD62L<sup>high</sup>, but also as CD16<sup>low</sup>/CD62L<sup>low</sup>. This last population may represent an immature  
284 neutrophil subset, marked by low levels of CD10. In addition, COVID-19 critical patients present higher  
285 plasmatic levels of G-CSF, accompanied by an emergency myelopoiesis and early neutrophil release from  
286 the bone marrow,<sup>67-70</sup> explaining the expansion of CD16<sup>low</sup> immature neutrophils.<sup>69</sup> In agreement, we  
287 observed that severe and critical patients showed increased percentages of CD114<sup>+</sup> neutrophils, the G-  
288 CSF receptor.

289 Most importantly, our study provides new insights about the impact of the PCNA scaffold on neutrophil  
290 heterogeneity and functions, therefore proposing that PCNA may orchestrate dedicated functions in  
291 specific subsets. Indeed, PCNA-S100A8 interaction was detected in conventional neutrophils, which  
292 display a very homogeneous CD16<sup>high</sup>/CD62L<sup>high</sup> phenotype. By contrast, in neutrophils from severe and  
293 critical COVID-19 patients, we observed a dramatic increase in the intensity of this interaction but also a  
294 radical switch to the CD16<sup>high</sup>/CD62L<sup>low</sup> subset in which this interaction was the most intense. Pertinently,  
295 this PCNA-S100A8<sup>high</sup> subset had increased ROS production, and increased CD11b and LOX1 expression as  
296 compared to the conventional CD16<sup>high</sup>/CD62L<sup>high</sup> subset. Nonetheless, this PCNA-S100A8<sup>high</sup> subset is not  
297 immature since no decreased CD10 expression was observed compared to the main CD16<sup>high</sup>/CD62L<sup>high</sup>  
298 subset. Further investigations are required to decipher the immunomodulatory functions of this PCNA-  
299 S100A8<sup>high</sup> subset<sup>70</sup> which accounts for more than 10% of the circulating neutrophils in COVID-19 patients  
300 and which may be considered as a pathogenic and pro-inflammatory subpopulation. Accordingly,  
301 inhibiting the molecular interaction between PCNA and S100A8 would provide a unique opportunity to  
302 target this pro-inflammatory subset of neutrophils without affecting the general neutrophil population,  
303 thereby avoiding neutropenia to maintain an efficient anti-infectious defense.

304 In conclusion, we propose that the increased neutrophil cytosolic PCNA is involved in the profound  
305 immune dysregulation observed in patients with severe COVID-19. Decoding the entire scaffold would  
306 certainly provide new insights into the molecular and functional dysregulation of neutrophils in patients  
307 with COVID-19.

## 308 **Materials and methods**

### 309 **Human blood samples**

310 Individuals hospitalized due to COVID-19 from April 2020 to January 2022 were recruited in Paris, at the  
311 Cochin Hospital from the Internal Medicine department (authorization #2019-3677), the Respiratory  
312 medicine department (authorization #2020 #A02700-39) and from the Intensive Care Medicine  
313 department (authorization #2018 #A01934-51) and at Bichat Hospital from the Intensive Care Medicine  
314 department (authorization #2020-715). This study was approved by the Hospital Ethics Committee,  
315 according to the Declaration of Helsinki. Each patient gave written informed consent and was classified  
316 into different clinical severity groups (Table 1) depending on a multifactorial score taking into account  
317 oxygen requirement.<sup>34-36</sup> Blood from COVID-19 patients and from healthy donors (HD) obtained from the  
318 *Etablissement Francais du Sang* was collected in EDTA-vacuum or in dry tubes for serum collection.  
319 Neutrophils were isolated in LPS-free dextran sedimentation and Ficoll (Histopaque-1077<sup>®</sup>, Sigma-Aldrich)  
320 centrifugation, as previously described.<sup>22</sup>

321

### 322 **Quantification of circulating neutrophil-derived activation markers**

323 Circulating neutrophil elastase (ThermoFisher Scientific), calprotectin (S100A8/A9) (Biotechne) and  
324 Neutrophil Extracellular Traps (NETs) were measured by ELISA as previously described<sup>37</sup>.

325

### 326 **Neutrophil phenotype assessment using spectral flow cytometry**

327 Blood neutrophils from HD or COVID-19 patients were labelled with the following antibodies: CD66b,  
328 CD15, CD62L, CD16, CD11b, CXCR2, PD-1, CD45, CD10, CD33, CD114, PDL-1, GLUT-1, LOX-1 or their  
329 respective isotypes (Table 3). Samples were acquired in a Cytex Aurora cytometer (Cytex Biosciences,  
330 Fremont, CA, USA). Data were analyzed using FlowJo v10.7.1 software (FlowJo LLC) (Supplemental Figure  
331 1). Neutrophil phenotype was also evaluated by unsupervised analysis using the t-SNE dimensional  
332 reduction algorithm. A sample of 30000 neutrophils (CD15<sup>+</sup> cells) from each individual were normalized  
333 and pulled down. Then, cells were grouped and subjected to the algorithm to form homogeneous clusters  
334 based on CD16, CD62L, CD10, CD11b, CD66b and LOX-1 surface expression using the CytoBank platform  
335 (Beckman Coulter Life Sciences, California).

336

### 337 **Assessment of physiological apoptosis**

338 Neutrophils (2 x 10<sup>6</sup> cells/mL in RPMI-1640-10% FBS) were incubated overnight (16h, 37°C, 5% CO<sub>2</sub>) and  
339 then labeled with annexin-V (Miltenyi Biotec) and 7-AAD (BD Biosciences) as previously described.<sup>22</sup> To

340 assess mitochondrial integrity, neutrophils were stained with 1  $\mu$ M of 3,3'-dihexyloxacarbocyanine iodide  
341 (DiOC6), a fluorescent dye selective for live cell mitochondria<sup>38,39</sup> (ThermoFisher). Data acquisition was  
342 performed using BD-Accuri™-C6Plus, analyzed by Cflow Plus software.

343

#### 344 **Evaluation of NADPH-oxidase-dependent ROS production**

345 Isolated neutrophils ( $0.1 \times 10^6$  cells) were suspended in 0.1 mL HBSS with or without T2AA (Sigma-Aldrich)  
346 at indicated concentrations for 1 h (37°C, 5% CO<sub>2</sub>). Neutrophils were then stimulated with or without PMA  
347 (Sigma-Aldrich; 0.1  $\mu$ g/ml), IgG- and complement proteins-opsonized zymosan (0.5 mg/mL), or N-Formyl-  
348 methionine-leucyl-phenylalanine (f-MLF) (Sigma-Aldrich; 10  $\mu$ M) as previously described (Ohayon et al  
349 2019). Chemiluminescence was recorded after addition of luminol (Sigma-Aldrich; 10  $\mu$ M) at 37°C in a  
350 TRISTAR luminometer (Bertold, Wild bad Germany) over time. The data were expressed as integrated total  
351 counts, processed by the microWim software and analyzed using Prism 9.3 software. In order to  
352 characterize the membrane phenotype of ROS-producing neutrophils, cells were first loaded with 10  $\mu$ M  
353 of cell-permeant 2',7'-dichlorodihydrofluorescein diacetate (DCF-DA, Thermo Fisher) and were stimulated  
354 with or without PMA or opsonized zymosan and were next stained with a mix of anti-human CD16 and  
355 CD62L to determine neutrophil subpopulations. Samples were acquired in a Cytex Aurora (Cytex  
356 Biosciences, Fremont, CA, USA) cytometer and approximately 100 000 gated events were used in each  
357 analysis (Supplemental Figure 1). Data were analyzed using FlowJo v10.7.1 software (FlowJo LLC).

358

#### 359 **Western blot analysis of PCNA and S100A8**

360 Neutrophil cytosol was obtained by sonication in a hypotonic HEPES buffer (50 mM) supplemented with  
361 inhibitors (4 mM PMSF, 400  $\mu$ M leupeptin, 400  $\mu$ M pepstatin, 1 mM orthovanadate, 1 mM EGTA, and 1  
362 mM EDTA) and DTT (1 mM), with a Soniprep 150 Plus sonicator (1 Hz for 10 s) as previously described.<sup>40</sup>  
363 Alternatively, neutrophils were lysed in the sonication buffer supplemented with 1% NP40 detergent to  
364 obtain a whole cell lysate. Protein concentration was measured using the BCA kit (Pierce). Samples diluted  
365 into Laemmli buffer (30  $\mu$ g per well) were subjected to SDS-PAGE, transferred to polyvinylidene difluoride  
366 (PVDF) membrane (PerkinElmer Life Sciences). After blocking with Tris-buffered saline (TBS) containing  
367 5% nonfat dry milk, membranes were probed with mouse monoclonal anti-PCNA (PC10; 1:1000 dilution),  
368 goat polyclonal anti-S100A8 (Everest, EB11513; 1:1000 dilution), goat polyclonal anti-actin (Sigma A2066;  
369 1:1000 dilution) antibodies overnight at 4°C. Secondary horseradish peroxidase-conjugated-linked anti-  
370 rabbit IgG (Jackson Lab, 111-035-003; 1:5000), anti-mouse IgG (Jackson Lab, 115-036-006; 1:2000) or anti-  
371 goat IgG (Santa Cruz biotechnology, sc-2033; 1:4000) antibodies were applied 1h at room temperature as

372 previously described (Witko-Sarsat et al 2010). Immunoreactivity was visualized using enhanced  
373 chemiluminescence reagents (Amersham Biosciences). Images were acquired and quantified using a  
374 Fusion FX7 system imaging (Vilbert Lourmat).

375

#### 376 **PCNA and S100A8 detection using indirect immunofluorescence or the Duolink<sup>®</sup> proximity ligation assay** 377 **(PLA)**

378 Cells were fixed in 2% formaldehyde/PBS for 20 min on ice and permeabilized with 0.25% Triton X-100 for  
379 5 min at room temperature, followed by ice-cold methanol for 10 min, incubated with the rabbit  
380 polyclonal anti-PCNA (Ab5; 1:25) or the mouse monoclonal anti-S100A8 (2H2; 1:100) antibodies for 45  
381 min. PCNA incubation was followed by biotinylated anti-rabbit IgG (Dako; 1:200) for 30 min, and then by  
382 streptavidin-coupled Alexa Fluor 555 (Invitrogen; 1:1000) for 30 min. S100A8 incubation was followed by  
383 anti-mouse IgG Alexa Fluor 488 (Invitrogen; 1:100) for 30 min. Nuclei were stained with DAPI containing  
384 mounting media (Sigma Aldrich) as previously described.<sup>22</sup> Red fluorescence was observed with a 488–  
385 560 nm-long-pass emission filter under 543 nm laser illumination. Images were processed using ImageJ  
386 software version 1.53J (National Institutes of Health) and fluorescence normalized to DAPI fluorescence  
387 as previously described

388 For Duolink<sup>®</sup> PLA assay, neutrophils ( $0.3 \times 10^6$ ) were processed as described by the manufacturer using a  
389 mix of anti-PCNA (Ab5; 1:100) and anti-S100A8 (2H2; 1:100) as primary antibodies either on cytopins or  
390 in suspension for microscopic or flow cytometry analysis, respectively. Detection was achieved if distance  
391 between the two targeted epitopes are up to 40 nm. Fluorescence was acquired under microscopy  
392 (Widefield Zeiss Observer Z1 and SR Leica SP8X STED Flim) or by FACS (Cytek Aurora) gating at least 100  
393 000 neutrophils. Data were analyzed using ImageJ 1.53J and FlowJo v10.7.1 softwares, respectively.

394

#### 395 **Analysis of PCNA-S100A8 interaction by surface plasmon resonance (SPR)**

396 PCNA was obtained using *E. coli* vector expression and purification as previously described<sup>30</sup>. Interactions  
397 between PCNA and recombinant human (rh) S100 proteins (R&D systems, Biotechne, MN, USA) were  
398 studied by SPR on a Biacore T200 (GE Healthcare) designed to calculate affinity and kinetic parameters as  
399 previously described.<sup>22,31</sup> Briefly PCNA was covalently immobilized on a dextran layer sensor chip (CM5)  
400 while the rh S100A8 (9876-S8), S100A9 (9254-S9) or S100A8/A9 (8226-S8) (1:1 complex) protein at the  
401 indicated concentrations (0.1–2  $\mu$ M) were used as analytes in a running buffer as previously described. In  
402 all experiments, the specific binding signal was obtained by subtracting the background signal. For global  
403 fitting we used kinetic titration on the Biacore T200 system, referred to as multiple-cycle kinetics, to



404 collect binding data for kinetic analysis. This method involves sequential injections of several analyte  
405 concentrations over the ligand immobilized on the sensor chip surface after a regeneration step between  
406 successive injections by 5 mM EDTA. The association ( $K_a$ ) and dissociation ( $K_d$ ) rate constants and  $K_D$  were  
407 calculated using BIAevaluation software. The simplest 1:1 Langmuir binding model was first tested. The  
408 heterogeneous ligand model was used as it significantly increased the statistical goodness-of-fit based on  
409 the  $\chi^2$  value as calculated by Biacore software. This model accounts for the presence of two sites that  
410 bind analyte independently of each other.

411

#### 412 **Statistical analysis**

413 Data are expressed as mean  $\pm$  standard error of the mean (SEM) from (n) independent experiments  
414 performed on neutrophils isolated from different donors or patients and analyzed by one-way ANOVA  
415 followed by Dunnett's or Tukey's test. For paired comparisons, Student's t-test was used. GraphPad  
416 Prism Software 9.0 was used for data processing (\* $P < 0.05$ ; \*\* $P < 0.01$ ; \*\*\* $P < 0.001$  were considered  
417 statistically significant).

#### 418 **Online supplemental material**

419 Supplemental Figure 1. Representative gate strategy used for neutrophils analysis by flow cytometry.

420 Supplemental Figure 2. Re-analysis of publicly available RNA-seq data of PCNA and S100A8. Expression of  
421 PCNA and S100A8/A9 genes in circulating and respiratory tract-infiltrated neutrophils from COVID-19  
422 patients.

423 Supplemental Figure 3. Concentration-response curve of T2AA, a PCNA inhibitor, in the activation of  
424 NADPH-oxidase in neutrophils from healthy controls and critical COVID-19 patients.

425 Supplemental Figure 4. Phenotypic characterization of whole blood neutrophils in COVID-19 patients.

426 Supplemental Figure 5. Phenotypic characterization of low-density-neutrophils in the PBMCin COVID-19  
427 patients.

428 **Author contributions**

429 All named authors meet the general criteria for authorship of this manuscript and have given final  
430 approval for publication. ROF, LP, LT, SM, VK, KB, MA and VWS designed experiments and analyzed data;  
431 ROF, LP, VK, SM, ML, LT, TD, MS, ELR, EPL, PF, VG, LCM, FS, CR, MC performed experiments; MHN, AH,  
432 SCM, PRB, LM, CM, FP contributed with critical reagents/tools/clinical samples; ROF, LP, ML, LT and VWS  
433 wrote the manuscript.

434

435

436 **Acknowledgments**

437 We are grateful for the excellent technical help provided by Giovanni Saraceni-Tasso to isolate  
438 neutrophils and to measure the respiratory burst, Thomas Guilbert (IMAGIC/Institut Cochin) and Nicolas  
439 Cagnard (Bioinformatics Core Platform/Imagine Institute) for the technical support. We thank Molly  
440 Ingersoll and Karen Aymonnier for review and feedback on the manuscript.

441 This study was supported by the Fondation pour la Recherche Médicale Grant EQU202003010155 (VWS)  
442 and the Investissements d'Avenir programme ANR-11-IDEX-0005-02, Sorbonne Paris Cite, LabEx  
443 INFLAMEX (VWS); the French National Research Agency (ANR) with the Grant RA-COVID-19 V5-  
444 COVINNATE (MHN); Grant DENDRISEPSIS ANR-17-CE15-0003 (FP); Grant APCOD ANR-17-CE15-0003-01  
445 (FP); the Sao Paulo research Foundation Grant FAPESP-SCRIPPS 15/50387-4 (FS)

446

447

448 **Disclosure of Conflicts of Interest**

449 The authors declare no conflict of interest.

450



451 **REFERENCES**

- 452 1. Nauseef WM, Borregaard N. Neutrophils at work. *Nat Immunol*. 2014;15(7):602–611.
- 453 2. Castanheira FVS, Kubes P. Neutrophils and NETs in modulating acute and chronic inflammation. *Blood*.
- 454 2019;133(20):2178–2185.
- 455 3. Soehnlein O, Steffens S, Hidalgo A, Weber C. Neutrophils as protagonists and targets in chronic
- 456 inflammation. *Nat Rev Immunol*. 2017;17(4):248–261.
- 457 4. Dinauer MC. Inflammatory consequences of inherited disorders affecting neutrophil function. *Blood*.
- 458 2019;133(20):2130–2139.
- 459 5. Silvestre-Roig C, Fridlender ZG, Glogauer M, Scapini P. Neutrophil Diversity in Health and Disease.
- 460 *Trends Immunol*. 2019;40(7):565–583.
- 461 6. Allen L-AH, Criss AK. Cell intrinsic functions of neutrophils and their manipulation by pathogens. *Curr*
- 462 *Opin Immunol*. 2019;60:124–129.
- 463 7. Hidalgo A, Chilvers ER, Summers C, Koenderman L. The Neutrophil Life Cycle. *Trends Immunol*.
- 464 2019;40(7):584–597.
- 465 8. Kobayashi SD, Malachowa N, DeLeo FR. Neutrophils and Bacterial Immune Evasion. *J Innate Immun*.
- 466 2018;10(5–6):432–441.
- 467 9. Long Q-X, Tang X-J, Shi Q-L, et al. Clinical and immunological assessment of asymptomatic SARS-CoV-
- 468 2 infections. *Nat Med*. 2020;26(8):1200–1204.
- 469 10. Ribes A, Vardon-Bouines F, Mémier V, et al. Thromboembolic events and Covid-19. *Adv Biol Regul*.
- 470 2020;77:100735.
- 471 11. Lucas C, Wong P, Klein J, et al. Longitudinal analyses reveal immunological misfiring in severe COVID-
- 472 19. *Nature*. 2020;584(7821):463–469.
- 473 12. Gustine JN, Jones D. Immunopathology of Hyperinflammation in COVID-19. *Am J Pathol*.
- 474 2021;191(1):4–17.
- 475 13. Li S, Jiang L, Li X, et al. Clinical and pathological investigation of patients with severe COVID-19. *JCI*
- 476 *Insight*. 2020;5(12):138070.
- 477 14. Paludan SR, Mogensen TH. Innate immunological pathways in COVID-19 pathogenesis. *Sci Immunol*.
- 478 2022;7(67):eabm5505.
- 479 15. Reyes L, A Sanchez-Garcia M, Morrison T, et al. A type I IFN, prothrombotic hyperinflammatory
- 480 neutrophil signature is distinct for COVID-19 ARDS-. *Wellcome Open Res*. 2021;6:38.
- 481 16. Silvin A, Chapuis N, Dunsmore G, et al. Elevated Calprotectin and Abnormal Myeloid Cell Subsets
- 482 Discriminate Severe from Mild COVID-19. *Cell*. 2020;182(6):1401-1418.e18.
- 483 17. Guo Q, Zhao Y, Li J, et al. Induction of alarmin S100A8/A9 mediates activation of aberrant neutrophils
- 484 in the pathogenesis of COVID-19. *Cell Host Microbe*. 2021;29(2):222-235.e4.
- 485 18. Pepper RJ, Hamour S, Chavele K-M, et al. Leukocyte and serum S100A8/S100A9 expression reflects
- 486 disease activity in ANCA-associated vasculitis and glomerulonephritis. *Kidney Int*. 2013;83(6):1150–
- 487 1158.
- 488 19. Jarlborg M, Courvoisier DS, Lamacchia C, et al. Serum calprotectin: a promising biomarker in
- 489 rheumatoid arthritis and axial spondyloarthritis. *Arthritis Res Ther*. 2020;22(1):105.
- 490 20. Pruenster M, Vogl T, Roth J, Sperandio M. S100A8/A9: From basic science to clinical application.
- 491 *Pharmacol Ther*. 2016;167:120–131.
- 492 21. Schenten V, Plançon S, Jung N, et al. Secretion of the Phosphorylated Form of S100A9 from
- 493 Neutrophils Is Essential for the Proinflammatory Functions of Extracellular S100A8/A9. *Front*
- 494 *Immunol*. 2018;9:447.
- 495 22. Witko-Sarsat V, Mocek J, Bouayad D, et al. Proliferating cell nuclear antigen acts as a cytoplasmic
- 496 platform controlling human neutrophil survival. *J Exp Med*. 2010;207(12):2631–2645.

- 497 23. Witko-Sarsat V, Ohayon D. Proliferating cell nuclear antigen in neutrophil fate. *Immunol Rev.*  
498 2016;273(1):344–356.
- 499 24. Kelman Z. PCNA: structure, functions and interactions. *Oncogene.* 1997;14(6):629–640.
- 500 25. Moldovan G-L, Pfander B, Jentsch S. PCNA, the maestro of the replication fork. *Cell.* 2007;129(4):665–  
501 679.
- 502 26. Bouayad D, Pederzoli-Ribeil M, Mocek J, et al. Nuclear-to-cytoplasmic relocalization of the  
503 proliferating cell nuclear antigen (PCNA) during differentiation involves a chromosome region  
504 maintenance 1 (CRM1)-dependent export and is a prerequisite for PCNA antiapoptotic activity in  
505 mature neutrophils. *J Biol Chem.* 2012;287(40):33812–33825.
- 506 27. Witko-Sarsat V, Pederzoli-Ribeil M, Hirsch E, et al. Regulating neutrophil apoptosis: new players enter  
507 the game. *Trends Immunol.* 2011;32(3):117–124.
- 508 28. Punchihewa C, Inoue A, Hishiki A, et al. Identification of small molecule proliferating cell nuclear  
509 antigen (PCNA) inhibitor that disrupts interactions with PIP-box proteins and inhibits DNA replication.  
510 *J Biol Chem.* 2012;287(17):14289–14300.
- 511 29. Inoue A, Kikuchi S, Hishiki A, et al. A small molecule inhibitor of monoubiquitinated Proliferating Cell  
512 Nuclear Antigen (PCNA) inhibits repair of interstrand DNA cross-link, enhances DNA double strand  
513 break, and sensitizes cancer cells to cisplatin. *J Biol Chem.* 2014;289(10):7109–7120.
- 514 30. Ohayon D, De Chiara A, Chapuis N, et al. Cytoplasmic proliferating cell nuclear antigen connects  
515 glycolysis and cell survival in acute myeloid leukemia. *Sci Rep.* 2016;6:35561.
- 516 31. Ohayon D, De Chiara A, Dang PM-C, et al. Cytosolic PCNA interacts with p47phox and controls NADPH  
517 oxidase NOX2 activation in neutrophils. *J Exp Med.* 2019;216(11):2669–2687.
- 518 32. Kerkhoff C, Nacken W, Benedyk M, et al. The arachidonic acid-binding protein S100A8/A9 promotes  
519 NADPH oxidase activation by interaction with p67phox and Rac-2. *FASEB J.* 2005;19(3):467–469.
- 520 33. Berthier S, Nguyen MVC, Baillet A, et al. Molecular interface of S100A8 with cytochrome b558 and  
521 NADPH oxidase activation. *PLoS One.* 2012;7(7):e40277.
- 522 34. Lee EE, Hwang W, Song K-H, et al. Predication of oxygen requirement in COVID-19 patients using  
523 dynamic change of inflammatory markers: CRP, hypertension, age, neutrophil and lymphocyte  
524 (CHANeL). *Sci Rep.* 2021;11(1):13026.
- 525 35. Mellado-Artigas R, Ferreyro BL, Angriman F, et al. High-flow nasal oxygen in patients with COVID-19-  
526 associated acute respiratory failure. *Crit Care.* 2021;25(1):58.
- 527 36. Hvarfner A, Al-Djaber A, Ekström H, et al. Oxygen provision to severely ill COVID-19 patients at the  
528 peak of the 2020 pandemic in a Swedish district hospital. *PLoS One.* 2022;17(1):e0249984.
- 529 37. Peyneau M, Granger V, Wicky P-H, et al. Innate immune deficiencies are associated with severity and  
530 poor prognosis in patients with COVID-19. *Sci Rep.* 2022;12(1):638.
- 531 38. Moriceau S, Kantari C, Mocek J, et al. Coronin-1 is associated with neutrophil survival and is cleaved  
532 during apoptosis: potential implication in neutrophils from cystic fibrosis patients. *J Immunol.*  
533 2009;182(11):7254–7263.
- 534 39. Tait SWG, Green DR. Mitochondria and cell death: outer membrane permeabilization and beyond.  
535 *Nat Rev Mol Cell Biol.* 2010;11(9):621–632.
- 536 40. Everts-Graber J, Martin KR, Thieblemont N, et al. Proteomic analysis of neutrophils in ANCA-  
537 associated vasculitis reveals a dysregulation in proteinase 3-associated proteins such as annexin-A1  
538 involved in apoptotic cell clearance. *Kidney Int.* 2019;96(2):397–408.
- 539 41. Chua RL, Lukassen S, Trump S, et al. COVID-19 severity correlates with airway epithelium–immune  
540 cell interactions identified by single-cell analysis. *Nat Biotechnol.* 2020;38(8):970–979.
- 541 42. Chen L, Long X, Xu Q, et al. Elevated serum levels of S100A8/A9 and HMGB1 at hospital admission are  
542 correlated with inferior clinical outcomes in COVID-19 patients. *Cell Mol Immunol.* 2020;17(9):992–  
543 994.

- 544 43. Pillay J, Kamp VM, van Hoffen E, et al. A subset of neutrophils in human systemic inflammation inhibits  
545 T cell responses through Mac-1. *J Clin Invest.* 2012;122(1):327–336.
- 546 44. Barnes BJ, Adrover JM, Baxter-Stoltzfus A, et al. Targeting potential drivers of COVID-19: Neutrophil  
547 extracellular traps. *J Exp Med.* 2020;217(6):e20200652.
- 548 45. Zhang Y, Wang Q, Mackay CR, Ng LG, Kwok I. Neutrophil subsets and their differential roles in viral  
549 respiratory diseases. *J Leukoc Biol.* 2022;111(6):1159–1173.
- 550 46. Cavalcante-Silva LHA, Carvalho DCM, Lima É de A, et al. Neutrophils and COVID-19: The road so far.  
551 *Int Immunopharmacol.* 2021;90:107233.
- 552 47. Hazeldine J, Lord JM. Neutrophils and COVID-19: Active Participants and Rational Therapeutic Targets.  
553 *Front Immunol.* 2021;12:680134.
- 554 48. Veras FP, Pontelli MC, Silva CM, et al. SARS-CoV-2-triggered neutrophil extracellular traps mediate  
555 COVID-19 pathology. *J Exp Med.* 2020;217(12):e20201129.
- 556 49. Nathan C. Neutrophils and COVID-19: Nots, NETs, and knots. *J Exp Med.* 2020;217(9):e20201439.
- 557 50. Wilk AJ, Lee MJ, Wei B, et al. Multi-omic profiling reveals widespread dysregulation of innate  
558 immunity and hematopoiesis in COVID-19. *J Exp Med.* 2021;218(8):e20210582.
- 559 51. Koenig LM, Boehmer DFR, Metzger P, et al. Blocking inflammation on the way: Rationale for CXCR2  
560 antagonists for the treatment of COVID-19. *J Exp Med.* 2020;217(9):e20201342.
- 561 52. González-Magaña A, Blanco FJ. Human PCNA Structure, Function and Interactions. *Biomolecules.*  
562 2020;10(4):E570.
- 563 53. Wang S-C. PCNA: a silent housekeeper or a potential therapeutic target? *Trends Pharmacol Sci.*  
564 2014;35(4):178–186.
- 565 54. Sprenkeler EGG, Zandstra J, van Kleef ND, et al. S100A8/A9 Is a Marker for the Release of Neutrophil  
566 Extracellular Traps and Induces Neutrophil Activation. *Cells.* 2022;11(2):236.
- 567 55. Kim DH, Choi E, Lee J-S, et al. House Dust Mite Allergen Regulates Constitutive Apoptosis of Normal  
568 and Asthmatic Neutrophils via Toll-Like Receptor 4. *PLoS One.* 2015;10(5):e0125983.
- 569 56. Kim DH, Gu A, Lee J-S, et al. Suppressive effects of S100A8 and S100A9 on neutrophil apoptosis by  
570 cytokine release of human bronchial epithelial cells in asthma. *Int J Med Sci.* 2020;17(4):498–509.
- 571 57. Gilljam KM, Feyzi E, Aas PA, et al. Identification of a novel, widespread, and functionally important  
572 PCNA-binding motif. *J Cell Biol.* 2009;186(5):645–654.
- 573 58. Prestel A, Wichmann N, Martins JM, et al. The PCNA interaction motifs revisited: thinking outside the  
574 PIP-box. *Cell Mol Life Sci.* 2019;76(24):4923–4943.
- 575 59. Spijkerman R, Bongers SH, Bindels BJJ, et al. Flow cytometric evaluation of the neutrophil  
576 compartment in COVID-19 at hospital presentation: A normal response to an abnormal situation. *J*  
577 *Leukoc Biol.* 2021;109(1):99–114.
- 578 60. Schulte-Schrepping J, Reusch N, Paclik D, et al. Severe COVID-19 Is Marked by a Dysregulated Myeloid  
579 Cell Compartment. *Cell.* 2020;182(6):1419–1440.e23.
- 580 61. Lourda M, Dzidic M, Hertwig L, et al. High-dimensional profiling reveals phenotypic heterogeneity and  
581 disease-specific alterations of granulocytes in COVID-19. *Proc Natl Acad Sci U S A.*  
582 2021;118(40):e2109123118.
- 583 62. Spijkerman R, Jorritsma NKN, Bongers SH, et al. An increase in CD62Ldim neutrophils precedes the  
584 development of pulmonary embolisms in COVID-19 patients. *Scand J Immunol.* 2021;93(6):e13023.
- 585 63. Kwok I, Becht E, Xia Y, et al. Combinatorial Single-Cell Analyses of Granulocyte-Monocyte Progenitor  
586 Heterogeneity Reveals an Early Uni-potent Neutrophil Progenitor. *Immunity.* 2020;53(2):303–318.e5.
- 587 64. Combadière B, Adam L, Guillou N, et al. LOX-1-Expressing Immature Neutrophils Identify Critically-Ill  
588 COVID-19 Patients at Risk of Thrombotic Complications. *Front Immunol.* 2021;12:752612.
- 589 65. Mukund K, Nayak P, Ashokkumar C, et al. Immune Response in Severe and Non-Severe Coronavirus  
590 Disease 2019 (COVID-19) Infection: A Mechanistic Landscape. *Front Immunol.* 2021;12:738073.

- 591 66. deKay JT, Emery IF, Rud J, et al. DEsprHigh neutrophils are associated with critical illness in COVID-19.  
592 *Sci Rep.* 2021;11(1):22463.
- 593 67. Shi H, Zuo Y, Yalavarthi S, et al. Neutrophil calprotectin identifies severe pulmonary disease in COVID-  
594 19. *J Leukoc Biol.* 2021;109(1):67–72.
- 595 68. Metzemaekers M, Cambier S, Blanter M, et al. Kinetics of peripheral blood neutrophils in severe  
596 coronavirus disease 2019. *Clin Transl Immunology.* 2021;10(4):e1271.
- 597 69. Bongers SH, Chen N, van Grinsven E, et al. Kinetics of Neutrophil Subsets in Acute, Subacute, and  
598 Chronic Inflammation. *Front Immunol.* 2021;12:674079.
- 599 70. Marini O, Costa S, Bevilacqua D, et al. Mature CD10+ and immature CD10– neutrophils present in G-  
600 CSF–treated donors display opposite effects on T cells. *Blood.* 2017;129(10):1343–1356.
- 601
- 602

603 **FIGURE LEGENDS**

604 **Figure 1. PCNA is overexpressed in the cytosol of neutrophils and is associated with COVID-19**  
605 **severity. (A-B)** Western blot analysis of PCNA expression in neutrophils cytosols from HD (n = 17),  
606 moderate (n = 5), severe (n = 6), and critical (n = 12) COVID-19 patients. **(A)** Representative  
607 experiment. **(B)** Quantification of Western blots. Data are expressed as fold change in reference  
608 to PCNA expression in HD. **(C-D)** Neutrophils from HD (n = 5), severe or critical COVID-19 patients  
609 (n = 5) were labeled with a rabbit polyclonal anti-PCNA antibody and with DAPI to visualize nuclei  
610 using the Widefield Zeiss Observer Z1 microscope (magnification x 100). **(C)** Representative  
611 experiment of indirect immunofluorescent staining of PCNA showing its cytosolic localization  
612 (red) and the nuclei (blue). **(D)** Quantification of the PCNA immunolabelling fluorescence. Photos  
613 were captured from at least 3 different fields for a given donor and each point corresponds to  
614 the mean of a different donor. **(E-G)** Soluble inflammation markers were measured: **(E)** NETs, as  
615 MPO-DNA complexes; **(F)** Elastase and **(G)** S100A8/A9 (calprotectin), by ELISA in serum from HD  
616 (n = 12) moderate (n = 7) severe (n = 18) and critical (n = 17) COVID-19 patients. **(H-J)** Correlation  
617 between normalized cytosolic PCNA expression measured by Western blot in neutrophils from  
618 patients with all levels of COVID-19 severity (as in B) and the circulating concentration of **(H)** NETs  
619 **(I)** Elastase and **(J)** Calprotectin. Pearson correlation coefficient are indicated and the associated  
620 probability is: \*\*p = 0.007, \*p = 0.014 and \*p = 0.024, respectively. Graph symbols represent  
621 individual donors. In B, D, E, F, and G data are presented as mean ± SEM. Data was analyzed by  
622 one way-ANOVA followed by Tukey or Dunnett post-test or by Student's t-test when two  
623 individual groups were compared (\*p<0.05; \*\*p<0.01; \*\*\*p<0.001).

624  
625 **Figure 2. Increased neutrophils survival in COVID-19 is reversed by the PCNA inhibitor T2AA.**  
626 **(A-D)** Spontaneous apoptosis was induced by overnight incubation of neutrophils from HD (n =  
627 10) severe or critical COVID-19 patients (n = 10) at 37°C, 5% CO<sub>2</sub> for 16 h in the presence or  
628 absence of the PCNA inhibitor T2AA (5 μM) **(A)** Percentage of viable neutrophils with annexin-  
629 V<sup>+</sup>/7-AAD<sup>+</sup> labelling. **(B)** Percentage of apoptotic neutrophils with annexin-V<sup>+</sup>/7-AAD<sup>-</sup> labelling.  
630 **(C)** Percentage of necrotic neutrophils with annexin-V<sup>+</sup>/7-AAD<sup>+</sup> labelling. **(D)** Flow cytometry  
631 measurement of DiOC6 labelling to assess mitochondria integrity. MFI of DiOC6 staining is

632 indicative of intact mitochondrial membrane potential and is decreased upon apoptosis. **(E)** PCNA  
633 expression measured by Western blot in cytosols from freshly isolated neutrophils at basal state  
634 [B] or following a 16h-incubation triggering spontaneous apoptosis [A]. PCNA abundance was  
635 quantified by densitometry and normalized using Ponceau red staining. Data are the mean of  
636 three independent experiments carried out with neutrophils from HD and COVID-19 patients  
637 with different disease severity (moderate, severe, or critical). In A, B, C and D, graph symbols  
638 represent individual donors. Data are presented as mean  $\pm$  SEM and were analyzed by one way-  
639 ANOVA followed by Tukey or Dunnett post-test or by Student's t-test when two individual groups  
640 were compared (\*\* $p < 0.001$ ).

641  
642 **Figure 3. PCNA regulates NADPH oxidase-dependent ROS production in COVID-19.** NADPH  
643 oxidase activation was assessed by using luminol-enhanced chemiluminescence (CL) that  
644 measured ROS production in isolated neutrophils from HD ( $n = 7$ ), moderate ( $n = 8$ ), severe ( $n =$   
645  $14$ ) and critical ( $n = 17$ ) COVID-19 patients under **(A)** basal or following stimulation by **(B)** PMA  
646 ( $0.1 \mu\text{g/mL}$ ), **(C)** opsonized zymosan ( $0.5 \text{ mg/mL}$ ) or **(D)** f-MLF ( $1 \mu\text{M}$ ). These measurements were  
647 performed in the absence or in the presence of the PCNA inhibitor, T2AA ( $5 \mu\text{M}$ ). CL was recorded  
648 at  $37^\circ\text{C}$  in a Tristar<sup>TM</sup> luminometer over time and data were expressed as arbitrary units (AU) at  
649 the peak of ROS production. **(E-F)** Assessment of the PCNA-p47<sup>phox</sup> interaction in neutrophils. The  
650 Duolink<sup>®</sup> proximity ligation assay (PLA) was performed on isolated neutrophils from HD ( $n=5$ ) or  
651 severe or critical COVID-19 patients ( $n=5$ ). Neutrophils were incubated in the absence or in the  
652 presence of PMA for 10 min to trigger NADPH oxidase activation. **(E)** Representative experiment  
653 of PLA staining using rabbit polyclonal anti-PCNA antibody associated with mouse monoclonal  
654 anti- p47<sup>phox</sup> antibody showing the interaction of PCNA and p47<sup>phox</sup> (red) and the nuclei labelled  
655 by DAPI (blue) and visualized using the Widefield Zeiss Observer Z1 microscope (magnification  $\times$   
656  $100$ ). **(F)** Quantification of the PCNA-p47<sup>phox</sup> proximity-induced fluorescence. Photos were  
657 captured from at least 3 different fields for a given donor and MFI was analyzed, each point  
658 corresponds to the mean of a different donors. Graph symbols represent individual donors. Data  
659 are presented as mean  $\pm$  SEM. Data was analyzed by one way-ANOVA followed by Tukey or



660 Dunnett post-test or by Student's t-test when two individual groups were compared (\* $p < 0.05$ ;  
661 \*\*\* $p < 0.001$ ).

662

663 **Figure 4. S100A8 is a partner of PCNA overexpressed in neutrophils cytosols from COVID-19**  
664 **patients. (A)** Data represent overlays of sensorgrams resulting from injection of human  
665 recombinant S100A8 at different concentrations (0.1 – 2  $\mu\text{M}$ ). Fits with a statistic  $\chi^2$  value 7.6 are  
666 shown as dotted lines (RU: response units). SPR experiments were performed on a Biacore T200  
667 apparatus. Kinetic values determination is reported in Table 2. Interaction was predicted under  
668 a standard curve composed of baseline, association, equilibrium, and dissociation phases. **(B)** SPR  
669 measurements of human recombinant S100A8, S100A9 or S100A8/A9 (2  $\mu\text{M}$ ) binding on  
670 immobilized PCNA. **(C)** Representative experiment of the assessment of the PCNA-S100A8  
671 interaction in isolated neutrophils using the Duolink<sup>®</sup> proximity ligation assay (PLA). PCNA-  
672 S100A8 proximity-induced fluorescence was detected (red) using a rabbit polyclonal anti-PCNA  
673 and a mouse monoclonal anti-S100A8. Prior to experiment, neutrophils were incubated in the  
674 absence or presence of T2AA (5  $\mu\text{M}$ ) for 30 min. DAPI was used for nuclear staining (blue) Cells  
675 were visualized using the SR Leica SP8X STED Flim confocal microscope (magnification x100) **(D)**  
676 Quantification of the PCNA-S100A8 proximity-induced fluorescence. Photos were captured from  
677 at least 3 different fields for a given donor and MFI was analyzed, each point corresponds to the  
678 mean of a different donors (E) Western blot analysis of S100A8 expression in neutrophils cytosols  
679 from HD (n = 17), moderate (n = 5), severe (n = 6), and critical (n = 6) COVID-19 patients. **(F)**  
680 Quantification of S100A8 abundance by densitometry. Western blot analysis of actin was  
681 performed on the same membranes and used as a loading control for the normalization of PCNA  
682 expression. **(G)** Correlation between normalized PCNA and S100A8 expressions measured by  
683 Western blot in neutrophils from patients with all levels of COVID-19 severity. Pearson  
684 correlation coefficient are indicated and the associated probability is \*\* $p = 0.004$ . **(H-I)**  
685 Neutrophils from HD (n = 5), severe or critical COVID-19 patients (n = 5) were labeled with a  
686 mouse monoclonal anti-S100A8 antibody and with DAPI to visualize nuclei using the Widefield  
687 Zeiss Observer Z1 microscope (magnification x 100). **(H)** Representative experiment of S100A8  
688 immunofluorescent staining showing its cytosolic localization (red) and the nuclei (blue). **(I)**

689 Quantification of the S100A8 immunofluorescent staining. Photos were captured from at least 3  
690 different fields for a given donor and MFI was analyzed in each field. Graph symbols represent  
691 individual donors. Data were analyzed by one way-ANOVA followed by Tukey or Dunnett post-  
692 test or by Student's t-test for two groups and shown as mean  $\pm$  SEM (\*\*p<0.01; \*\*\*p<0.001).

693  
694 **Figure 5. Neutrophils in COVID-19 patients present an altered phenotype linked to activation**  
695 **and immaturity. (A)** Whole blood from HD (n = 7), severe (n = 10) and critical (n = 10) COVID-19  
696 patients were used for leukocytes staining and the assessment of 13 surface markers was  
697 performed by spectral flow cytometry on a Cytex Aurora cytometer. Analysis was conducted in  
698 CD15<sup>+</sup> cells using the gate strategies shown in Supplemental Figure 1. Results are expressed by  
699 MFI for each marker. **(B)** t-Distributed Stochastic Neighbor Embedding (t-SNE) plots showing  
700 neutrophil heterogeneity. Analysis was performed in CD15<sup>+</sup> cells (n = 30000 down sampled)  
701 comparing HD (n = 5), severe (n = 5) and critical (n = 5) COVID-19 patients. Data were analyzed  
702 by one way-ANOVA followed by Tukey or Dunnett post-test or by Student's t-test for two groups  
703 and shown as mean  $\pm$  SEM (\*\*p<0.01; \*\*\*p<0.001).

704  
705 **Figure 6. PCNA-S100A8 interaction is increased in an hyperactivated subset of neutrophils in**  
706 **COVID-19. (A)** Representative flow cytometry dot plot showing the distinct neutrophil subsets  
707 according to CD16 and CD62L membrane labelling in neutrophils (CD15<sup>+</sup> cells). Different subsets  
708 are observed in the HD compared to the COVID-19 patient. The percentages of positive cells (%)  
709 in the different CD16/CD62L neutrophil subsets that display CD16<sup>high</sup>/CD62L<sup>high</sup> (subset 1),  
710 CD16<sup>high</sup>/CD62L<sup>low</sup> (subset 2), CD16<sup>low</sup>/CD62L<sup>low</sup> (subset 3) and CD16<sup>low</sup>/CD62L<sup>high</sup> (subset 4)  
711 surface staining are presented. **(B)** Percentage of neutrophils in each CD16/CD62L subset.  
712 Neutrophil phenotyping was performed in blood from HD (n = 7), severe (n = 10) and critical  
713 (n=18) COVID-19 patients according to the gate strategy described in Supplemental Figure 1. **(C)**  
714 Flow cytometry quantification of the PCNA-S100A8 interaction by proximity-induced  
715 fluorescence using Duolink<sup>®</sup> in the different neutrophil subsets (1-4) according to CD16/CD62L  
716 surface expression. **(D)** Measurement of ROS production using dichlorofluorescein diacetate  
717 (DCFDA) labelling in the different neutrophil subsets (1-4) according to CD16/CD62L surface



718 expression. DCFDA-loaded neutrophils were next fixed and labeled for CD16 and CD62L surface  
719 expression. The expression of the surface markers **(E)** CD11b, (F) LOX-1 and **(G)** CD10 were also  
720 assessed in CD16/CD62L subset of neutrophils enriched in severe and critical COVID-19. Samples  
721 were acquired in a Cytex Aurora. Graph symbols represent individual donors. Data were analyzed  
722 by one way-ANOVA followed by Tukey or Dunnett post-test or by Student's t-test for two groups  
723 and shown as mean  $\pm$  SEM (\*\*p<0.01; \*\*\*p<0.001).

## TABLES

**Table 1.** Clinical and biological characteristics of patients

	COVID-19		
	Moderate (n=15)	Severe (n = 21)	Critical (n19)
Male sex (n/%)	8 / 53.3%	14 / 66.7%	16 / 84.2%
Female sex (n/%)	7 / 46.7%	7 / 33.3%	3 / 15.8%
Age* (years)	76.9 ± 3.3 (42-89)	68.7 ± 11.3 (44-92)	64.6 ± 2,4 (48-77)
Leukocytes** (/μl)	5910.7± 650	7367.5±2180.5	9326.5±1110
Neutrophils** (/μL)	4206.43±665.2	5971.4±2150.3	8135.26±1123.5
CRP** (mg/dL)	NA	46.3±13	90.3±18.7
D-Dimer** (ng/ml)	1212±253	1444±910	3293±1295
Oxygenotherapy at inclusion (n)	6	21	17
Oxygen flow < 3L/mn (n)	5	2	2
Oxygen flow > 3L/mn (n)	1	10	10
Nasal high flow oxygen (n, (%))	0	9 (42.9%)	5 (29.4%)
Need for nasal high flow oxygen during hospitalization (n, (%))	4	15 (71.4%)	13 (68.4%)
Systemic corticotherapy (n)	6	20	17
Complete hospitalization duration (Days, Median (IQR))	16±2.5		15.7±3
Death (n)	0	1	7

\*Results are expressed as mean ± SEM (min-max); \*\*Results are expressed as mean ± SEM. NA: not available.

Moderate patients either do not require oxygen or require a flow of less than 3 L/min. Severe patients require COVID-19 oxygen flow between or over 3 L/min. Critically ill patients require more than 60% high flow oxygen and ventilation and have been recruited in the Intensive Care Unit (ICU).

**Table 2.** Kinetics and affinity of PCNA interaction with S100A8


PCNA/S100A8						
Immobilized ligand/Soluble analyte	$K_{a1}$ ( $M^{-1} s^{-1}$ )	$K_{d1}$ ( $s^{-1}$ )	$K_{a2}$ ( $M^{-1} s^{-1}$ )	$K_{d2}$ ( $s^{-1}$ )	$K_D$ (M)	$Chi^2$
Heterogenous ligand model	2199	0.1035	138.1	0.0034	$4.7 \times 10^{-5}$ ( $K_{D1}$ )	7.6
					$2.49 \times 10^{-5}$ ( $K_{D2}$ )	
1:1 model	158.5	0.00568	NA	NA	$3.58 \times 10^{-5}$	16.6

Binding of S100A8 (0.1-2  $\mu$ M) was measured as described in Materials and Methods section. Values were calculated for 1:1 and heterogeneous ligand models. The heterogeneous ligand model accounts for two different binding sites on the immobilized PCNA, and the two corresponding dissociation constants ( $K_{D1}$  and  $K_{D2}$ ) were determined. NA = not applicable.


**Table 3.** Antibodies used for the phenotyping of neutrophils by flow cytometry.

<b>Surface marker</b>	<b>clone</b>	<b>Commercial source</b>
CD66b	G10F5	BioLegend
CD15	W6D3	BD Biosciences
CD62L	DREG-56	BioLegend
CD16	3G8	BioLegend
CD11b	ICRF44	BioLegend
CXCR2	5E8	BioLegend
PD-1	EH12.1	BD Biosciences
CD45	2D1	BioLegend
CD10	HI10a	BD Biosciences
CD33	P67.6	BD Biosciences
CD114	LMM741	BD Biosciences
PDL-1	MH3	BioLegend
GLUT-1	1418G	R&D Systems
LOX-1	15C4	BioLegend


**Figure 1. Formiga et al.**




**Figure 2. Formiga et al.**



**Figure 3. Formiga et al.**





**Figure 4. Formiga et al.**





**Figure 5. Formiga et al.**



**Figure 6. Formiga et al.**

